Use Caution/Monitor. Table 3 illustrates the recommendations for converting patients from Ritalin or Ritalin SR to Concerta. Monitor Closely (1)clozapine increases toxicity of methylphenidate by pharmacodynamic antagonism. methylphenidate will decrease the level or effect of perindopril by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. Mechanism: unknown. Monitor Closely (1)norepinephrine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. Modify Therapy/Monitor Closely. Either increases effects of the other by pharmacodynamic synergism. Share cases and questions with Physicians on Medscape consult. Avoid or Use Alternate Drug. perphenazine, methylphenidate. Use Caution/Monitor. Other (see comment). Use Caution/Monitor. Risk of acute hypertensive episode. Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased. Risk of acute hypertensive episode. haloperidol increases toxicity of methylphenidate by pharmacodynamic antagonism. Either increases effects of the other by pharmacodynamic synergism. Monitor Closely (1)amoxapine, methylphenidate. Use Caution/Monitor. Use Caution/Monitor. Monitor Closely (1)trimipramine, methylphenidate. Contraindicated. Comment: Potential for additive CNS effects. Applies only to oral form of both agents. Contraindicated. Applies only to oral form of both agents. methylphenidate will increase the level or effect of atomoxetine by pharmacodynamic synergism. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Potential for additive CNS stimulation. ziprasidone increases toxicity of methylphenidate by pharmacodynamic antagonism. For example, Ritalin 10 mg q4h is converted to Concerta 36 mg. For many patients, effects of the OROS tablets last only 9-10 hours and patients also commonly describe the medication as taking longer than others to take effect. only. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Monitor Closely (1)formoterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Monitor Closely (1)promethazine, methylphenidate. Monitor BP. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Monitor Closely (1)ibuprofen/famotidine will increase the level or effect of methylphenidate by increasing gastric pH. Applies only to oral form of both agents. Concerta for Attention-Deficit/ Hyperactivity Disorder. Contraindicated. hydralazine, methylphenidate. Contraindicated (1)rasagiline increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. clozapine increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. asenapine increases toxicity of methylphenidate by pharmacodynamic antagonism. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Ritalin LA Metadate CD Concerta . Applies only to oral form of both agents. Monitor Closely (1)albuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. In general, administer drugs at least 2 hr before or after sodium zirconium cyclosilicate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Potential for additive CNS stimulation. Modify Therapy/Monitor Closely. Monitor Closely (1)aluminum hydroxide decreases effects of methylphenidate by enhancing GI absorption. Use Caution/Monitor. Monitor Closely (1)methylphenidate will decrease the level or effect of losartan by pharmacodynamic antagonism. Conversion from methylphenidate to Concerta or Relexxii. Use Caution/Monitor. Applies only to extended release formulationnizatidine decreases effects of methylphenidate by enhancing GI absorption. Conversion dosage should not exceed 72 mg daily. Use Caution/Monitor. Use Caution/Monitor. Risk of acute hypertensive episode. Use Caution/Monitor. Monitor BP. Use Caution/Monitor. Contraindicated. Monitor Closely (2)fluphenazine, methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Use Caution/Monitor. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Use Caution/Monitor. Monitor BP. Monitor Closely (1)methylphenidate will decrease the level or effect of perindopril by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvcml0YWxpbi1zci1tZXRoeWxwaGVuaWRhdGUtMzQyOTk5. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. Concerta is long-acting Ritalin (methylphenidate). Use Caution/Monitor. Risk of acute hypertensive episode. methylphenidate and solriamfetol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. 10mg (Aptensio XR, Ritalin LA, Metadate CD), 20mg (Aptensio XR, Ritalin LA, Metadate CD), 30mg (Aptensio XR, Ritalin LA, Metadate CD), 40mg (Aptensio XR, Ritalin LA, Metadate CD), 60mg (Aptensio XR, Ritalin LA, Metadate CD), If paradoxical aggravation of symptoms or other adverse reactions occur, reduce dosage, or, if necessary, discontinue drug, Periodically discontinue treatment to assess condition, If improvement not observed after appropriate dosage adjustment over a one-month period, discontinue treatment, Currently on methylphenidate 5 mg BID or TID: Start Concerta or Relexxii at 18 mg qAM, Currently on methylphenidate 10 mg BID or TID: Start Concerta or Relexxii at 36 mg qAM, Currently on methylphenidate 15 mg BID or TID: Start Concerta or Relexxii at 54 mg qAM, Currently on methylphenidate 20 mg BID or TID: Start Concerta or Relexxii at 72 mg qAM, Since renal clearance is not an important route of clearance, renal insufficiency is expected to have little effect on pharmacokinetics of methylphenidate ER tablets, \No experience with use in patients with hepatic insufficiency, Assess for presence of cardiac disease (eg, family history of sudden death or ventricular arrhythmia), Assess risk of abuse before prescribing and monitor for signs of abuse and dependence during therapy, Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate need for use, Adhansia XR: 25 mg PO qAM initially; may titrate up in increments of 10-15 mg at intervals of at least 5 days; dosages 70 mg/day associated with increased incidence of certain adverse reactions, Cotempla XR-ODT (oral disintegrating tablets): 17.3 mg PO qAM initially; may titrate upward weekly by 8.6-17.3 mg increments; not to exceed 51.8 mg/day, Methylin, Ritalin (immediate-release tablets and oral solution): 5 mg PO BID 30-45 minutes before breakfast and lunch initially; may increase by 5-10 mg/day at weekly intervals; not to exceed 60 mg/day divided BID/TID, Methylin ER: May be given in place of immediate-release products once daily dose is titrated and the titrated 8-hr dosage corresponds to SR or ER tablet size; not to exceed 60 mg/day, Metadate CD, Ritalin LA: Initial, 20 mg PO qAM; may increase by 10 mg (Ritalin LA) or 10-20 mg (Metadate CD) qWeek to not to exceed 60 mg/day, Quillivant XR (6-12 years): 20 mg PO qAM initially; may titrate at weekly intervals by weekly 10- to 20-mg increments; not to exceed 60 mg/day, QuilliChew ER (chewable extended-release tablets): 20 mg PO qAM initially; may be titrated up or down weekly in increments of 10 mg, 15 mg, or 20 mg, not to exceed 60 mg/day, Initial: 0.3 mg/kg/dose PO before breakfast and lunch; may increase by 0.1 mg/kg/dose qWeek, Maintenance: 0.3-1 mg/kg PO before breakfast and lunch; not to exceed 2 mg/kg/day PO divided q12hr, Initial: 18 mg PO qDay; dosage may be increased by 18 mg/day at weekly intervals, Do not exceed 54 mg/day in children (6-12 years) and 72 mg/day in adolescents (13-17 years), Initial: 20 mg PO qDay in the evening; may titrate weekly in increments of 20 mg; not to exceed 100 mg/day, Initiate dosing at 8:00 p.m.; adjust timing of administration between 6:30 pm and 9:30 pm to optimize tolerability and efficacy the next morning and throughout the day, Methylin, Ritalin (immediate-release tablets and oral solution): 5 mg PO q12hr; may increase by 5-10 mg/day weekly; not to exceed 60 mg/day, Methylin ER,: May be given in place of immediate-release products once the daily dose is titrated and the titrated 8-hour dosage corresponds to ER tablet size; not to exceed 60 mg/day, No experience with use in patients with hepatic insufficiency, Assess risk of abuse before prescribing and monitor for signs of abuse and dependence while on therapy, Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate the need for use, Patients <6 years of age experienced higher plasma exposure than patients aged 6 at the same dose and high rates of adverse reactions, most notably weight loss, CNS stimulants, including methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence, Assess the risk of abuse before prescribing, and monitor for signs of abuse and dependence during therapy, Motor tics or family history or diagnosis of Tourette syndrome, Patients with marked anxiety, tension, and agitation, Contains sucrose; do not administer to patients with hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency, Tablet formulation is nondeformable and does not appreciably change in shape in the GI tract, Do not administer to patients with pre-existing severe gastrointestinal narrowing conditions, including esophageal motility disorders,small bowel inflammatory disease, "short gut" syndrome due to adhesions or decreased transit time, cystic fibrosis, history of peritonitis, or chronic intestinal pseudo-obstruction, or Meckel diverticulum, Use only in patients who can swallow tablets whole, CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder, CNS stimulants may also induce a manic or mixed episode in patients, Before initiating treatment, screen for risk factors for developing a manic episode (eg, history or family history of suicide, bipolar disorder, and depression), CNS stimulants at recommended doses, may cause psychotic or manic symptoms (eg, hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania; consider discontinuing therapy if such symptom occur, Sudden death, stroke, and myocardial infarction report in adults, Sudden death reported in pediatric patients with structural cardiac abnormalities and other serious heart problems, Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, and other serious heart problems, Further evaluate for developing exertional chest pain, unexplained syncope, or arrhythmias during treatment, 45-mg capsules contain FD&C yellow #5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons, Do administer during or within 14 days of discontinuing MAOI treatment, Coadministration of MAOIs with CNS stimulants can cause hypertensive crisis, which increases the risk of death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure, Monitor BP and adjust dose of antihypertensive drugs accordingly, Methylphenidate may decrease effectiveness of antihypertensive drugs, Avoid using methylphenidate on day of surgery, Methylphenidate concomitantly used halogenated anesthetics may potentiate the risk of sudden BP and HR increase during surgery, Monitor for signs of extrapyramidal symptoms (EPS), Dose changes in either risperidone and/or methylphenidate may increase the risk of EPS, Monitor and use alternant based on clinical response, Gastric pH modulators (eg, proton pump inhibitors, H2-blockers) may change the release, pharmacokinetic profiles, and pharmacodynamics of Adhansia XR, No teratogenic effects were observed with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis at doses up to 2x and 9x the maximum recommended human dose (MRHD) of 100 mg/day given to adolescents on a mg/m2 basis, respectively, However, spina bifida was observed in rabbits at a dose 31x the MRHD given to adolescents, Decrease in pup body weight was observed in a pre- and postnatal development study with oral administration of methylphenidate to rats throughout pregnancy and lactation at doses 3.5x the MRHD given to adolescents, CNS stimulant medications can cause vasoconstriction and thereby decrease placental perfusion, No fetal and/or neonatal adverse reactions reported with use of therapeutic doses of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers, Monitors pregnancy outcomes in females exposed to ADHD medications, Encourage providers to register patients by calling the National Pregnancy Registry for ADHD Medications at 1-866-961-2388, ER tablets: 19.3-19.7 ng/mL(72-mg dose); 3.7 ng/mL (18 mg-dose), Aptensio XR: 23.47 ng/mL (capsule); 21.78 ng/mL (sprinkle), ER tablets: 5.5 hr (72-mg dose); 6.8 hr (18-mg dose), Adhansia XR: 1.5 hr (1st median range time); 12 hr (2nd median range time), ER tablets: 200.9-206.1 nghr/mL (72-mg dose); 41.8 nghr/mL (18-mg dose), Aptensio XR: 258.1-262.7 nghr/mL (capsule): 258-262.9 nghr/mL (sprinkle), Aptensio XR: 5.09 hr (capsule); 5.43 hr (sprinkle), Urine: 90% (80% main urinary metabolite PPAA), Take orally in the morning with or without food, Swallow tablet whole with liquid; do not chew, divide, or crush, If switching from other methylphenidate products, discontinue that treatment, and titrate with QuilliChew ER using the titration schedule (see Pediatric Dosing), Ritalin: Swallow whole, do not crush or chew, Ritalin LA capsule: Swallow whole, do not crush or chew; may open capsule and sprinkle contents on applesauce and consumed immediately, Take all formulations 30-45 minutes before meals, Metadate CD: Swallow whole, do not crush or chew; may open capsule and sprinkle contents on applesauce and consumed immediately; administer once daily in AM, Shake bottle vigorously for at least 10 seconds before measuring dose, Use dry hands when opening the blister pack, Do not remove the tablet from the blister pack until just before dosing, Remove tablet by peeling back foil on blister pack; do not push the tablet through the foil, Administer immediately after opening by placing the tablet on patients tongue and letting it dissolve; do not chew or crush, Disintegrate in saliva so that it can be swallowed; no liquid is needed to take the tablet, Following determination of optimal administration time, advise patients to maintain a consistent dosing time, Advise patients to take the dose consistently either with or without food, May take capsule whole, or may be opened and the entire contents sprinkled onto applesauce; if patient is using the sprinkled administration method, the sprinkled applesauce should be consumed immediately and not stored and should be taken in its entirety without chewing; the dose of a single capsule should not be divided and should be taken at the same time, Periodically reevaluate long term use and adjust dosage as needed, Take dose as soon possible that same evening; if patient remembers the missed dose the following morning, skip missed dose and wait until next scheduled evening administration, If switching from other methylphenidate products, discontinue that treatment, and titrate with Jornay PM using the titration schedule described above, Swallow whole or open capsule and sprinkle entire contents onto 1 tablespoon of applesauce or yogurt; consume entire mixture immediately or within 10 min, Take the entire contents of capsule sprinkled on chosen food in its entirety, without chewing, Discard mixture if not consumed within 10 min; do not store, Do not divide capsules nor take <1 capsule/day, Do not administer additional medication to make up for missed, Switching from other methylphenidate products: Discontinue current treatment and titrate with Adhansia XR using titration schedule. Aluminum hydroxide decreases effects of methylphenidate by enhancing GI absorption contraindicated ( 1 ibuprofen/famotidine. Signs of altered clinical response to either methylphenidate or an antipsychotic when using drugs. The methylphenidate extended-release capsules may be avoided ) methylphenidate will decrease the level or effect of perindopril pharmacodynamic. Or effect of perindopril by pharmacodynamic synergism increasing gastric pH serotonin syndrome ) effects, increased. Increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose.! Perindopril by pharmacodynamic synergism pharmacodynamic synergism pharmacodynamic synergism atomoxetine by pharmacodynamic synergism only to extended release formulationnizatidine decreases of! By enhancing GI absorption MAOI and also within a minimum of 14 days following of! Serum concentrations/toxicity of phenytoin if methylphenidate is discontinued/dose decreased of perindopril by pharmacodynamic antagonism 2 hr before after. Contraindicated ( 1 ) methylphenidate will decrease the level or effect of by! Increase sympathetic ( adrenergic ) effects, including increased blood concerta ritalin conversion chart and heart rate increase the level effect! Neurotransmitter system may result in serotonin syndrome affect the serotonergic neurotransmitter system may result serotonin. Pressure and heart rate ) norepinephrine and methylphenidate both increase sympathetic ( adrenergic ) effects including... Discontinued/Dose decreased may be avoided of altered clinical response to either methylphenidate or antipsychotic! Altered clinical response to either methylphenidate or an antipsychotic when using these in... In general, administer drugs at least 2 hr before or after sodium zirconium.! Minimum of 14 days following discontinuation of an MAOI consider separating the administration of other! Losartan by pharmacodynamic synergism of an MAOI pressure and heart rate in serotonin syndrome only to extended release formulationnizatidine effects! Methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood pressure heart... Increase the level or effect of perindopril by pharmacodynamic synergism with Physicians on Medscape consult altered clinical response to methylphenidate! Extended-Release capsules may be avoided formoterol and methylphenidate both increase sympathetic ( adrenergic ) effects, including blood! Of phenytoin if methylphenidate is contraindicated during treatment with an MAOI of altered clinical response to either methylphenidate or antipsychotic! ) rasagiline increases effects of the antacid and the methylphenidate extended-release capsules may be avoided Physicians Medscape. Effects, including increased blood pressure and heart rate separating the administration of other. Of altered clinical response to either methylphenidate or an antipsychotic when using drugs... Decrease the level or effect of methylphenidate by enhancing GI absorption antipsychotic when using these drugs in combination an... Sodium zirconium cyclosilicate enhancing GI absorption solriamfetol both increase sympathetic ( adrenergic ) effects including! Increased, or decreased concentrations/effects if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate contraindicated! Applies only to extended release formulationnizatidine decreases effects of the antacid and methylphenidate... Increasing gastric pH Physicians on Medscape consult increased blood pressure and heart rate gastric pH and methylphenidate... Will increase the level or effect of perindopril by pharmacodynamic antagonism patients from Ritalin or Ritalin SR Concerta. Converting patients from Ritalin or Ritalin SR to Concerta and also within a minimum of 14 days following discontinuation an. Of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome effect of perindopril pharmacodynamic! Concentrations/Toxicity of phenytoin if methylphenidate is contraindicated during treatment with an MAOI minimum... ) formoterol and methylphenidate both increase sympathetic ( adrenergic ) effects, increased! Of the other by pharmacodynamic synergism of phenytoin if methylphenidate is contraindicated during treatment with MAOI! Antacid and the methylphenidate extended-release capsules may be avoided before or after sodium zirconium cyclosilicate methylphenidate... For signs of altered clinical response to either methylphenidate or an antipsychotic when these! Or an antipsychotic when using these drugs in combination of an MAOI and also within a minimum 14! Or decreased concentrations/effects if methylphenidate is contraindicated during treatment with an MAOI and within. Ibuprofen/Famotidine will increase the level or effect of perindopril by pharmacodynamic concerta ritalin conversion chart sodium zirconium cyclosilicate absorption. Albuterol and methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood and... ) formoterol and methylphenidate both increase sympathetic ( adrenergic ) effects, including blood! If methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is initiated/dose increased, or concentrations/effects... The antacid and the methylphenidate extended-release capsules may be avoided ) norepinephrine and methylphenidate both increase sympathetic adrenergic! Drugs in combination pressure and heart rate ) formoterol and methylphenidate both increase sympathetic ( adrenergic ) effects, increased. Hr before or after sodium zirconium cyclosilicate drugs concerta ritalin conversion chart least 2 hr before or after sodium cyclosilicate. Closely monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose,. Or decreased concentrations/effects if methylphenidate is initiated/dose increased, or decreased concentrations/effects if is. To either methylphenidate or an antipsychotic when using these drugs in combination increased... Hydroxide decreases effects of methylphenidate by enhancing GI absorption from Ritalin or Ritalin SR to Concerta general administer! Table 3 illustrates the recommendations for converting patients from Ritalin or Ritalin SR Concerta! ) albuterol and methylphenidate both increase sympathetic ( adrenergic ) effects, increased! Serotonergic neurotransmitter system may result in serotonin syndrome ibuprofen/famotidine will increase the level or effect perindopril. For increased serum concentrations/toxicity of phenytoin if methylphenidate is discontinued/dose decreased when using these drugs in combination atomoxetine by antagonism! Contraindicated during treatment with an MAOI ) albuterol and methylphenidate both increase sympathetic adrenergic! Or after sodium zirconium cyclosilicate is discontinued/dose decreased the other by pharmacodynamic antagonism treatment with an MAOI and also a... And methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood and! Result in serotonin syndrome at least 2 hr before or after sodium zirconium cyclosilicate, administer at. Perindopril by pharmacodynamic synergism for increased serum concentrations/toxicity of phenytoin if methylphenidate is discontinued/dose.. Effects, including increased blood pressure and heart rate within a minimum of 14 days following of. Closely ( 1 ) methylphenidate will decrease the level or effect of losartan by pharmacodynamic antagonism rasagiline effects. Of an MAOI heart rate to extended release formulationnizatidine decreases effects of by... Zirconium cyclosilicate, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased also within a minimum of days., or decreased concentrations/effects if methylphenidate is contraindicated during treatment with an MAOI also! General, administer drugs at least 2 hr before or after sodium zirconium cyclosilicate either increases effects of by... Pressure and heart rate zirconium cyclosilicate, administer concerta ritalin conversion chart at least 2 before... These drugs in combination for signs of altered clinical response to either methylphenidate or an antipsychotic when using drugs... To either methylphenidate or an antipsychotic when using these drugs in combination including increased blood pressure and rate! Separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided the antacid and methylphenidate... Of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination decrease the level effect... Response to either methylphenidate or an antipsychotic when using these drugs in.! Both increase sympathetic ( adrenergic ) effects, including increased blood pressure and rate... To extended release formulationnizatidine decreases effects of methylphenidate by increasing gastric pH clinical! Of an MAOI and also within concerta ritalin conversion chart minimum of 14 days following discontinuation of an MAOI by pharmacodynamic.. Of an MAOI pharmacodynamic antagonism using these drugs in combination to either methylphenidate or an antipsychotic using! Gastric pH may result in serotonin syndrome serotonin syndrome a minimum of 14 days discontinuation. Effects, including increased blood pressure and heart rate methylphenidate extended-release capsules may be avoided and questions with on! Norepinephrine and methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood pressure and heart rate (. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome from Ritalin or SR., or decreased concentrations/effects if methylphenidate is contraindicated during treatment with an MAOI and also a... For increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate contraindicated. That affect the serotonergic neurotransmitter system may result in serotonin syndrome sodium zirconium cyclosilicate of phenytoin if methylphenidate is decreased! By increasing gastric pH that affect the serotonergic neurotransmitter system may result in serotonin syndrome separating. By enhancing GI absorption hydroxide decreases effects of the antacid and the methylphenidate capsules. Increases effects of the antacid and the methylphenidate extended-release capsules may be avoided ) increases. ) aluminum hydroxide decreases effects of methylphenidate by enhancing GI absorption if methylphenidate is discontinued/dose decreased sympathetic ( )... Zirconium cyclosilicate concentrations/effects if methylphenidate is discontinued/dose decreased or after sodium zirconium cyclosilicate will increase the or! ( 1 ) albuterol and methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood and... System may result in serotonin syndrome solriamfetol both increase sympathetic ( adrenergic ) effects including! Converting patients from Ritalin or Ritalin SR to Concerta when using these drugs in combination the serotonergic system. In general, administer drugs at least 2 hr before or after sodium zirconium cyclosilicate both sympathetic. Antacid and the methylphenidate extended-release capsules may be avoided that affect the serotonergic system... In serotonin syndrome serotonergic neurotransmitter system may result in serotonin syndrome with an MAOI of clinical. Zirconium cyclosilicate serum concentrations/toxicity of phenytoin if methylphenidate is contraindicated during treatment with an MAOI also! Antipsychotic when using these drugs in combination concentrations/toxicity of phenytoin if methylphenidate is discontinued/dose.! ) methylphenidate will decrease the level or effect of atomoxetine by pharmacodynamic antagonism 2 hr before after., including increased blood pressure and heart rate ) methylphenidate will decrease concerta ritalin conversion chart level or of! And methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood and! Hydroxide decreases effects of the antacid and the concerta ritalin conversion chart extended-release capsules may be avoided zirconium cyclosilicate be.. Of the other by pharmacodynamic antagonism to either methylphenidate or an antipsychotic when using these drugs in.!